Global Nuclear Imaging Market By Overview
Introduction:
Nuclear Imaging Market was valued at US$ 3.5 Billion in 2024 and is projected to grow at a CAGR of 5.2% to reach US$ 5.5 Billion by 2034.
Nuclear imaging equipment is designed to solve the diagnostic challenges. It is used for diagnosing medical image using small amount of radioactive material and control the severity of or for treating various disease such as cancer, heart diseases, neurological disorders, and other abnormalities within the body. This attributes to the fact that it delivers noninvasive and unique information at the molecular and cellular level that is exclusive, and cannot be reproduced using other imaging procedures.
Drivers and Restraints:
Radioactive materials and isotopes used for diagnosis and treatment of diseases such as neurological disorders, gastrointestinal, cancers, heart disease, etc. are known as nuclear medicines. Nuclear imaging helps in identification of diseases at an early stage by observing molecular activity of cells within the body. Increasing prevalence of cancer among individuals globally, coupled with growing demand for accurate diagnosis and effective treatment by use of nuclear imaging are major factors driving growth of the global nuclear imaging market. Further, cancer rates could increase by 50%, i.e. to 15 million new cases by the year 2020, as per the World Cancer Report in 2018. It also states that healthy lifestyles and various public health initiatives by governments and health practitioners could originate this trend, and prevent as many as one-third of cancer cases, worldwide. In addition, increasing investments by governments and private sectors in R&D of nuclear medicines and advanced diagnostic technology and systems is another factor driving growth of the global market. However, major factors hampering growth of the global nuclear imaging market are high cost of diagnostic equipment and high cost of treatment. In addition, stringent government regulations for drug approval and drug usage is another factor hampering growth of the target market. Nevertheless, growing application of nuclear medicine in neurological applications is projected to create lucrative opportunities for major manufacturers in the global market over the forecast period.
Segmentation:
The nuclear imaging market is segmented based product, application, and region.
On the basis of product, the nuclear imaging market is segmented into equipment and radioisotope. Based on application, the target market is segmented into SPECT applications and PET applications. SPECT application segment is further classified into technetium-99m (TC-99m), thallium-201 (TI-201), gallium (Ga-67), iodine (I-123), and other SPECT radioisotopes. PET application segments is further segmented into oncology, cardiology, neurology, and other PET applications.
Based on region the nuclear imaging market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global nuclear imaging market in terms of revenue and is accounted to maintain its dominance over the forecast period. This is mainly attributed due to presence of major key manufacturers in this region. In addition, increasing investments by private players in R&D of new and advanced diagnostics and treatment technologies and nuclear medicines are also the major factors contributing for growth of the North America nuclear medicine market. The Europe nuclear medicine market is projected to witness considerable growth and is accounted to register a CAGR of 5.2% over the forecast period. The market in Asia Pacific is estimated to witness highest growth in terms of revenue, owing to rapid development of healthcare infrastructure in countries such as India, China, etc.
Key Players:
The key players operating the nuclear imaging market involves Bracco Imaging SpA, GE Healthcare, Cardinal Health Inc., Koninklijke Philips NV, Nordion (Canada) Inc., Siemens Healthineers, Curium, CMR NAVISCAN (GAMMA MEDICA INC.), NTP Radioisotopes SOC, and Toshiba Medical Systems Corporation. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in May 2018, Curium improved its position in the French PET market with the acquisition of Cyclopharma’s French commercial and manufacturing operations.
Detailed Segmentation:
Nuclear Imaging Market, By Product:
- Equipment
- Radioisotope
- Diagnostic Technology
- SPECT Radioisotopes
- Technetium-99m (TC-99m)
- Thallium-201 (TI-201)
- Gallium (Ga-67)
- Iodine (I-123)
- Other SPECT Radioisotopes
- PET Radioisotopes
- Fluorine-18 (F-18)
- Rubidium-82 (RB-82)
- Other PET Radioisotopes
- SPECT Radioisotopes
- Diagnostic Technology
Nuclear Imaging Market, By Application:
- SPECT Applications
- Cardiology
- Neurology
- Thyroid
- Other SPECT Applications
- PET Applications
- Oncology
- Cardiology
- Neurology
- Other PET Applications
Nuclear Imaging Market, By Region:
- North America
- Middle East & Africa
- Middle East & Africa Nuclear Imaging Market, By Product
- Middle East & Africa Nuclear Imaging Market, By Application
- Middle East & Africa Nuclear Imaging Market, By Country
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Latin America Nuclear Imaging Market, By Product
- Latin America Nuclear Imaging Market, By Application
- Latin America Nuclear Imaging Market, By Country
- Brazil
- Mexico
- Rest of Latin America
- Asia Pacific
- Asia Pacific Nuclear Imaging Market, By Product
- Asia Pacific Nuclear Imaging Market, By Application
- Asia Pacific Nuclear Imaging Market, By Country
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Europe
- Europe Nuclear Imaging Market, By Product
- Europe Nuclear Imaging Market, By Application
- Europe Nuclear Imaging Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- North America Nuclear Imaging Market, By Product
- North America Nuclear Imaging Market, By Application
- North America Nuclear Imaging Market, By Country
- U.S.
- Canada
- Middle East & Africa
Company Profile:
- Bracco Imaging SpA *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- GE Healthcare
- Cardinal Health Inc.
- Koninklijke Philips NV
- Nordion (Canada) Inc.
- Siemens Healthineers
- Curium
- CMR NAVISCAN (GAMMA MEDICA INC.)
- NTP Radioisotopes SOC
- Toshiba Medical Systems Corporation
“*” marked represents similar segmentation in other categories in the respective section
Global Nuclear Imaging Market By Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Industry Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Nuclear Imaging Strategies
- Key Questions this Study will Answer
- Market Snippet, By Product
- Market Snippet, By Application
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Product, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Equipment
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Radioisotope
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Diagnostic Technology
- PET Radioisotopes
- Fluorine-18 (F-18)
- Rubidium-82 (RB-82)
- Other PET Radioisotopes
- SPECT Radioisotopes
- Technetium-99m (TC-99m)
- Thallium-201 (TI-201)
- Gallium (Ga-67)
- Iodine (I-123)
- Other SPECT Radioisotopes
- PET Radioisotopes
- Overview
- Market Segmentation, By Application, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- SPECT Applications
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Cardiology
- Neurology
- Thyroid
- Other SPECT Applications
- PET Applications
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Oncology
- Cardiology
- Neurology
- Other PET Applications
- Overview
- Global Market, By Region, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Product, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Product, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Product, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Product, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Product, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
-
- Bracco Imaging SpA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- GE Healthcare
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Cardinal Health, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Koninklijke Philips NV
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Nordion (Canada), Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Siemens Healthineers
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Curium
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- CMR NAVISCAN (GAMMA MEDICA, INC.)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- NTP Radioisotopes SOC
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Toshiba Medical Systems Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Bracco Imaging SpA
-
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The nuclear imaging market is segmented based product, application, and region.
Emerging trends include the use of hybrid imaging systems (such as SPECT/CT and PET/CT), the development of new radiopharmaceuticals, and the application of artificial intelligence for image analysis. Opportunities arise from the increasing prevalence of cardiovascular and oncological disorders, advancements in imaging technology, and the expanding applications of nuclear imaging in research and clinical practice.
Key factors include the rising incidence of chronic diseases, the demand for early and accurate diagnosis, advancements in radiopharmaceuticals and imaging agents, and the growing importance of nuclear medicine in personalized and precision medicine. Additionally, the integration of nuclear imaging with other imaging modalities and the development of theranostics contribute to market growth.
Regions covered include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the market due to a well-established healthcare infrastructure, high prevalence of chronic diseases, and significant investments in nuclear medicine research. However, the Asia-Pacific region is witnessing substantial growth, driven by increasing healthcare expenditure, rising awareness of advanced medical imaging technologies, and the adoption of nuclear imaging in countries like China and India.
The key players operating the nuclear imaging market involves Bracco Imaging SpA, GE Healthcare, Cardinal Health Inc., Koninklijke Philips NV, Nordion (Canada) Inc., Siemens Healthineers, Curium, CMR NAVISCAN (GAMMA MEDICA INC.), NTP Radioisotopes SOC, and Toshiba Medical Systems Corporation.